Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.55 |
| ▸ | CASR | P41180 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259212 | 0.85 | ADRB2 (0.57) | ADRB2ADRB1CASR | |
| SCHEMBL11692760 | 0.84 | ADRB2 (0.58) | ADRB2ADRB1 | |
| SCHEMBL6399196 | 0.84 | ADRB3 (0.45) | ADRB2ADRB1 | |
| SCHEMBL6262196 | 0.81 | ADRB2 (0.40) | ADRB2ADRB1 | |
| SCHEMBL6258471 | 0.81 | ADRB2 (0.40) | ADRB2ADRB1 | |
| SCHEMBL28535211 | 0.75 | ADRA2A (0.62) | ADRB2ADRB1 | |
| SCHEMBL17670537 | 0.74 | ADRB2 (0.58) | ADRB2ADRB1 | |
| SCHEMBL11691981 | 0.74 | ADRB2 (0.55) | ADRB2ADRB1 | |
| SCHEMBL6264677 | 0.74 | DPP4 (0.39) | ADRB2ADRB1CASR | |
| Hydrochloric Acid SCHEMBL6399582 | 0.73 | ADRB2 (0.39) | ADRB2ADRB1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234134-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-20 | — | — | US | disclosed |
| US-6951888-B2 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-04 | — | — | US | disclosed |
| EP-1551792-A1 | NOVEL BETA MIMETICS WITH EXTENDED DURATION OF ACTION, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
| WO-2004033412-A1 | NOVEL BETA MIMETICS WITH EXTENDED DURATION OF ACTION, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234134-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | CHRM1, CHRM2, ADRB1 | ADRB2 5/4885ADRB1 3/4885CASR 888/4885 |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | ADRA2C, ADRA1D, ADRB1 | ADRB2 4/4885ADRB1 3/4885CASR 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.